KindlyMD Sees Unusually Large Options Volume (NASDAQ:NAKA)

KindlyMD, Inc. (NASDAQ:NAKA) was the recipient of some unusual options trading activity on Tuesday. Stock traders bought 48,276 call options on the stock. This is an increase of approximately 123% compared to the average daily volume of 21,621 call options.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NAKA shares. B. Riley cut their target price on shares of KindlyMD from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Thursday, November 20th. Maxim Group assumed coverage on shares of KindlyMD in a research report on Wednesday, September 3rd. They set a “buy” rating and a $8.00 price objective for the company. Zacks Research upgraded KindlyMD to a “hold” rating in a research note on Friday, October 17th. Wall Street Zen raised KindlyMD to a “sell” rating in a report on Saturday, October 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of KindlyMD in a report on Monday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.50.

KindlyMD Price Performance

NASDAQ:NAKA traded up $0.02 during trading hours on Tuesday, reaching $0.47. The stock had a trading volume of 10,446,393 shares, compared to its average volume of 9,395,824. The company has a market capitalization of $205.89 million, a PE ratio of -0.42 and a beta of 31.19. KindlyMD has a 52 week low of $0.43 and a 52 week high of $34.77. The company’s 50 day moving average price is $0.74.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.